AU732211C - Novel compound - Google Patents

Novel compound

Info

Publication number
AU732211C
AU732211C AU23928/99A AU2392899A AU732211C AU 732211 C AU732211 C AU 732211C AU 23928/99 A AU23928/99 A AU 23928/99A AU 2392899 A AU2392899 A AU 2392899A AU 732211 C AU732211 C AU 732211C
Authority
AU
Australia
Prior art keywords
novel compound
novel
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU23928/99A
Other languages
English (en)
Other versions
AU732211B2 (en
AU2392899A (en
Inventor
Andrew Simon Craig
Victor Witold Jacewicz
Alan David Jones
Deirdre O'keefe
Michael Urquhart
Neal Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU732211(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2392899A publication Critical patent/AU2392899A/en
Application granted granted Critical
Publication of AU732211B2 publication Critical patent/AU732211B2/en
Priority to AU2001100025A priority Critical patent/AU2001100025B4/en
Priority to AU2002100370A priority patent/AU2002100370A4/en
Publication of AU732211C publication Critical patent/AU732211C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU23928/99A 1998-07-02 1999-04-23 Novel compound Ceased AU732211C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001100025A AU2001100025B4 (en) 1999-04-23 2001-05-24 Novel compound
AU2002100370A AU2002100370A4 (en) 1998-07-02 2001-07-11 Novel compound

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GB9814316 1998-07-02
GB9821732 1998-10-06
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GB9902935 1999-02-10
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Related Child Applications (5)

Application Number Title Priority Date Filing Date
AU48821/99A Division AU724845B3 (en) 1998-07-02 1999-09-20 Novel compound
AU69567/00A Division AU732558B3 (en) 1998-07-02 2000-10-26 Novel compound
AU2001100025A Division AU2001100025B4 (en) 1999-04-23 2001-05-24 Novel compound
AU54307/01A Division AU5430701A (en) 1998-07-02 2001-07-11 Novel compound
AU2002100370A Division AU2002100370A4 (en) 1998-07-02 2001-07-11 Novel compound

Publications (3)

Publication Number Publication Date
AU2392899A AU2392899A (en) 2000-01-20
AU732211B2 AU732211B2 (en) 2001-04-12
AU732211C true AU732211C (en) 2004-05-06

Family

ID=27269380

Family Applications (4)

Application Number Title Priority Date Filing Date
AU23928/99A Ceased AU732211C (en) 1998-07-02 1999-04-23 Novel compound
AU23938/99A Ceased AU713877B3 (en) 1998-07-02 1999-04-23 Novel compound
AU36191/99A Abandoned AU3619199A (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
AU23937/99A Ceased AU713131B3 (en) 1998-07-02 1999-04-23 Novel compound

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU23938/99A Ceased AU713877B3 (en) 1998-07-02 1999-04-23 Novel compound
AU36191/99A Abandoned AU3619199A (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
AU23937/99A Ceased AU713131B3 (en) 1998-07-02 1999-04-23 Novel compound

Country Status (34)

Country Link
US (4) US6063927A (cg-RX-API-DMAC10.html)
EP (5) EP1020463A1 (cg-RX-API-DMAC10.html)
JP (1) JP2002519422A (cg-RX-API-DMAC10.html)
KR (1) KR20010053336A (cg-RX-API-DMAC10.html)
CN (1) CN1127502C (cg-RX-API-DMAC10.html)
AR (2) AR011759A1 (cg-RX-API-DMAC10.html)
AT (4) ATE251155T1 (cg-RX-API-DMAC10.html)
AU (4) AU732211C (cg-RX-API-DMAC10.html)
BE (3) BE1012403A5 (cg-RX-API-DMAC10.html)
BR (1) BR9911682A (cg-RX-API-DMAC10.html)
CA (1) CA2269999A1 (cg-RX-API-DMAC10.html)
CH (1) CH689805A8 (cg-RX-API-DMAC10.html)
DE (5) DE19918588A1 (cg-RX-API-DMAC10.html)
DK (7) DK1089996T3 (cg-RX-API-DMAC10.html)
ES (4) ES2158778B1 (cg-RX-API-DMAC10.html)
FI (2) FI4209U1 (cg-RX-API-DMAC10.html)
FR (2) FR2780728B1 (cg-RX-API-DMAC10.html)
GB (5) GB2367003A (cg-RX-API-DMAC10.html)
GR (3) GR990100140A (cg-RX-API-DMAC10.html)
HU (1) HUP0102334A3 (cg-RX-API-DMAC10.html)
IE (5) IES20000894A2 (cg-RX-API-DMAC10.html)
IL (1) IL140628A (cg-RX-API-DMAC10.html)
IT (1) IT1312540B1 (cg-RX-API-DMAC10.html)
LU (1) LU90388B1 (cg-RX-API-DMAC10.html)
NL (4) NL1011875C2 (cg-RX-API-DMAC10.html)
NO (1) NO319030B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ509180A (cg-RX-API-DMAC10.html)
PL (1) PL345214A1 (cg-RX-API-DMAC10.html)
PT (4) PT1089996E (cg-RX-API-DMAC10.html)
SE (1) SE9901462A0 (cg-RX-API-DMAC10.html)
SI (3) SI0970955T1 (cg-RX-API-DMAC10.html)
SK (1) SK20262000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200100054T2 (cg-RX-API-DMAC10.html)
WO (1) WO2000001694A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
CN1183988C (zh) * 1997-02-27 2005-01-12 味之素株式会社 析晶装置及析晶方法
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
HUP0303827A2 (hu) * 2000-08-28 2004-04-28 Synthon B.V. Paroxetinkészítmények és eljárások ezek előállítására
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
BRPI0609749A2 (pt) 2005-04-07 2011-10-18 Chata Biosystems sistema de acondicionamento de caminho de fluxo
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
MX2009009572A (es) * 2007-03-09 2009-12-08 Novartis Ag Sales de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-i-il)-quinazoli n-4-il]-pirrole-2, 5-di ona.
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
US20100249166A1 (en) * 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (cg-RX-API-DMAC10.html) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223430B1 (en) * 1985-10-21 1991-02-27 Honda Giken Kogyo Kabushiki Kaisha Method for controlling the solenoid current of a solenoid valve which controls the amount of suction of air in an internal combustion engine
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
MX9707585A (es) * 1995-04-03 1997-12-31 Abbott Lab Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
CN1068597C (zh) * 1995-05-17 2001-07-18 诺沃挪第克公司 制备4－芳基－哌啶衍生物的方法
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2234640A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
DE69739561D1 (de) * 1996-06-13 2009-10-15 Sumitomo Chemical Co Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
SK11812000A3 (sk) * 1998-02-06 2001-08-06 Smithkline Beecham Plc Soli paroxetínu, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
CA2323896A1 (en) * 1998-03-16 1999-09-23 Andrew Simon Craig Crystalline form of paroxetine
KR20010042552A (ko) * 1998-04-09 2001-05-25 피터 기딩스 파록세틴 말레에이트
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
CA2269999A1 (en) 2000-01-02
EP1020464A1 (en) 2000-07-19
EP1288214A1 (en) 2003-03-05
NO319030B1 (no) 2005-06-06
AU713877B3 (en) 1999-12-09
GB2336364A (en) 1999-10-20
FI4209U1 (fi) 1999-11-10
ATE251155T1 (de) 2003-10-15
GB2336364B (en) 2000-05-10
DE69900007T2 (de) 2001-06-07
DE69900007D1 (de) 2000-09-07
SI1020464T1 (en) 2001-12-31
US6063927A (en) 2000-05-16
GR3036208T3 (en) 2001-10-31
AU713131B3 (en) 1999-11-25
DK1020464T3 (da) 2001-09-24
US20020035130A1 (en) 2002-03-21
DK199900554A (da) 2000-01-03
NO991944L (no) 2000-01-03
WO2000001694A1 (en) 2000-01-13
IE990344A1 (en) 2000-05-03
GB2352395B (en) 2004-02-11
DK200000390U1 (da) 2000-12-27
CH689805A8 (fr) 2000-02-29
DE69911774T2 (de) 2004-08-05
DE29907248U1 (de) 1999-09-09
PT102291A (pt) 2000-05-31
SE9901462A0 (sv) 2000-01-03
IES990343A2 (en) 2000-01-02
IL140628A0 (en) 2002-02-10
SK20262000A3 (sk) 2001-07-10
PL345214A1 (en) 2001-12-03
FI990922A0 (fi) 1999-04-23
GR3034328T3 (en) 2000-12-29
DK0970955T3 (da) 2000-10-09
GB9920332D0 (en) 1999-11-03
LU90388B1 (fr) 2001-01-29
HK1037877A1 (en) 2002-02-22
PT102291B (pt) 2002-07-31
DK199900234U4 (da) 2000-12-22
ES2158778B1 (es) 2002-03-16
CN1127502C (zh) 2003-11-12
JP2002519422A (ja) 2002-07-02
EP1089996A1 (en) 2001-04-11
SI1089996T1 (en) 2004-04-30
NO991944D0 (no) 1999-04-23
DE69911774D1 (de) 2003-11-06
ATE195121T1 (de) 2000-08-15
EP1020463A1 (en) 2000-07-19
SI0970955T1 (en) 2001-02-28
IES81166B2 (en) 2000-05-31
EP0970955A1 (en) 2000-01-12
EP1089996B1 (en) 2003-10-01
FI990922L (fi) 2000-01-03
NL1012271C2 (nl) 1999-09-23
AT3185U3 (de) 2000-01-25
FR2780728A1 (fr) 2000-01-07
GB9909505D0 (en) 1999-06-23
GR990100140A (el) 2000-03-31
IE20000633A1 (en) 2001-10-17
HUP0102334A2 (hu) 2002-05-29
DE19918588A1 (de) 2000-01-27
DE60000003D1 (de) 2001-08-09
ES2158778A1 (es) 2001-09-01
PT1020464E (pt) 2001-10-30
IL140628A (en) 2004-06-20
CH689805A5 (fr) 1999-11-30
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
PT970955E (pt) 2000-11-30
BE1011664A6 (fr) 1999-11-09
US20020193406A1 (en) 2002-12-19
IES20000894A2 (en) 2001-05-30
FR2802098A1 (fr) 2001-06-15
GB0026487D0 (en) 2000-12-13
ES2157881T3 (es) 2001-09-01
TR200100054T2 (tr) 2001-06-21
NL1011875C2 (nl) 2000-03-24
DK199900234U1 (da) 2000-12-22
GB2339428A (en) 2000-01-26
ES2149044T3 (es) 2000-10-16
AU732211B2 (en) 2001-04-12
US20010023253A1 (en) 2001-09-20
FI112077B (fi) 2003-10-31
ITMI990866A1 (it) 2000-10-23
GB2367003A (en) 2002-03-27
AR011759A1 (es) 2000-09-13
DK199900176U3 (da) 1999-08-13
ATE202777T1 (de) 2001-07-15
NL1012272C1 (nl) 1999-07-12
DK1089996T3 (da) 2004-02-09
HUP0102334A3 (en) 2003-12-29
IT1312540B1 (it) 2002-04-22
GR1003350B (el) 2000-03-29
FIU990190U0 (fi) 1999-04-23
NL1011875A1 (nl) 2000-01-07
AU3619199A (en) 2000-01-24
CN1315949A (zh) 2001-10-03
BE1012420A6 (fr) 2000-10-03
ES2209428T3 (es) 2004-06-16
EP0970955B1 (en) 2000-08-02
FR2780728B1 (fr) 2001-02-16
DE60000003T2 (de) 2002-03-21
GB2377637A (en) 2003-01-22
EP1020464B1 (en) 2001-07-04
IES20000893A2 (en) 2001-05-30
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
BR9911682A (pt) 2001-12-26
AU2392899A (en) 2000-01-20
AR018197A1 (es) 2001-10-31
GB2352395A (en) 2001-01-31
KR20010053336A (ko) 2001-06-25
SE9901462L (cg-RX-API-DMAC10.html)
NZ509180A (en) 2001-06-29
SE9901462D0 (sv) 1999-04-23
AT3185U2 (de) 1999-11-25
NL1011874C1 (nl) 1999-07-12
BE1012403A5 (fr) 2000-10-03

Similar Documents

Publication Publication Date Title
AU732211C (en) Novel compound
AUPP796798A0 (en) New compound
AU2863899A (en) New compounds
AU4260199A (en) Novel compounds
AU2623899A (en) Novel thiobenzamides
AU1424200A (en) Compounds
AU4501699A (en) Aminoazole compounds
AU5980899A (en) Novel compounds
AU2014800A (en) Novel compounds
AU2350199A (en) Novel aminoorganofunctionalsiloxanes
AUPQ441499A0 (en) Novel compound
AU1434500A (en) Compounds
AU4814699A (en) Novel compounds
AUPP549998A0 (en) New compound
AU4037699A (en) Novel aryl-hydro naphthalenal kanamines
AU5516599A (en) Substituted 3-aryl-pyrazoles
AU2187799A (en) Novel taxaneterpine compounds
AU2724799A (en) Novel endo-xylogalacturonase
AU4507899A (en) Substituted n-aryl-o-alkyl-carbamates
AU4511499A (en) Substituted cyclooctadepsipeptides
AUPO691897A0 (en) New compound
AU2863799A (en) New compounds
AU2725599A (en) Substituted alxoxycarbonyl compounds
AUPP377198A0 (en) Novel compound WF00144
AU1192300A (en) Novel compounds

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: AMEND THE INVENTORS TO INCLUDE VICTOR WITOLD JACEWICZ AND MICHAEL URQUHART

SREP Specification republished
CB Opposition filed

Opponent name: SYNTHON B.V.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20030908

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20031211

CH Opposition withdrawn

Opponent name: SYNTHON B.V.